Table 2 Treatment characteristics, response, and toxicity.

From: Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Characteristics

n

%

Follow-up, months (median, range)

9.3 (0.2–26.1)

 

No. of induction cycles with CPX (median, range)

1 (1–2)

 

ANC recoverya in patients with CR/CRi after CPX-351 induction (n = 83)

 Yes

79

95

 No

4

5

 Time, days (median, range)

33 (6–99)

 

Platelet recoveryb in patients with CR/CRi after CPX-351 induction (n = 83)

 Yes

76

92

 No

7

8

 Time, days (median, range)

30 (7–77)

 

Response after induction (n = 179)

 CR/CRi

85

47

 MLFS

35

20

 Refractory disease

53

30

 Early death (<30 days) without response

6

3

 Evaluation

 MRD available in case of CR/CRi

36

42c

 MRD negative

23

64d

Grade III/IV non-hematologic toxicities (n = 188)

 Infection

41

22

 GI (mucositis, nausea, vomiting)

7

4

 Bleeding

7

4

 Renal failure

5

3

 Febrile neutropenia

28

15

 Pneumonia

42

22

Mortality on d30 after CPX-351 induction (n = 176)e

 Alive

162

92

 Dead

14

8

  1. ANC absolute neutrophile count, CR complete remission, CRi complete remission with incomplete hematologic recovery, d day, GI gastrointestinal, MLFS morphologic leukemia-free state, MRD minimal residual disease, n number, SD stable disease, PD progressive disease, n.d. not done.
  2. Numbers in parentheses display patients with available information.
  3. aDefined as ANC > 500/µl.
  4. bDefined as platelet count >50,000/µl.
  5. cOf the 85 patients with CR/CRi.
  6. dOf the 36 patients with available MRD results.
  7. ePatients proceeding to allo-HSCT before d30 following CPX-351 induction have been excluded.
Back to article page